Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive publishing date : 2021 - 09 - 16 save search
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06
Published: 2021-09-16 (Crawled : 23:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.44%
H: 0.47%
C: -0.15%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -0.7%
H: 2.3%
C: 2.23%
positive results
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
Published: 2021-09-16 (Crawled : 23:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
prostate cancer positive therapy cancer
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Published: 2021-09-16 (Crawled : 23:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
treatment positive therapy results phase 3 trial cell carcinoma
PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
Published: 2021-09-16 (Crawled : 14:00) - biospace.com/
PMCB | $2.2 0.0% 11K
|
Manufacturing
|
| O: 14.37%
H: 2.88%
C: -8.38%
fda positive results positive results biotech iot
Vincerx Pharma Announces $50 Million Private PlacementStrengthened financial position extends expected cash runway into 2023
Published: 2021-09-16 (Crawled : 13:00) - biospace.com/
VINC | $0.8475 -5.83% -6.19% 350K
|
|
| O: 2.59%
H: 1.36%
C: -1.79%
positive pharma
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Published: 2021-09-16 (Crawled : 11:33) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.53%
H: 0.71%
C: -0.37%
phase 2 positive results topline
BeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress
Published: 2021-09-16 (Crawled : 11:00) - beyondspringpharma.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 0.35%
H: 0.95%
C: -2.34%
europe positive therapy plinabulin
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
Published: 2021-09-16 (Crawled : 11:00) - biospace.com/
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 10.51%
H: 1.37%
C: -1.1%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.72%
H: 1.18%
C: 0.9%
phase 2 europe positive trial her2+ her2- her2
Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress
Published: 2021-09-16 (Crawled : 07:00) - prnewswire.com
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
|
| O: 24.35%
H: 14.58%
C: 5.42%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.72%
H: 1.18%
C: 0.9%
positive
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.